MCID: VRL017
MIFTS: 35

Viral Hemorrhagic Fever

Categories: Gastrointestinal diseases, Genetic diseases, Infectious diseases, Rare diseases

Aliases & Classifications for Viral Hemorrhagic Fever

MalaCards integrated aliases for Viral Hemorrhagic Fever:

Name: Viral Hemorrhagic Fever 20 58
Hemorrhagic Fevers, Viral 70

Characteristics:

Orphanet epidemiological data:

58
viral hemorrhagic fever
Inheritance: Not applicable; Age of onset: All ages;

Classifications:

Orphanet: 58  
Rare infectious diseases


Summaries for Viral Hemorrhagic Fever

GARD : 20 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs. Orpha Number: 341 Definition Viral hemorrhagic fever is a group of recently discovered contagious viral infections characterized by severe, multiple, and often fatal hemorrhages. African fevers include Lassa fever discovered in 1969, Marburg's disease that first occurred in 1967, and Ebola fever that appeared in 1976. Other viruses may also cause hemorrhagic fevers (for example, arbovirus fever). Clinical description Regarding Lassa fever, after a 7-day incubation period, fever and ulcerating hemorrhagic pharyngitis occur, followed by pleuropneumonia. The disease then progresses to either spontaneous cure or to profuse digestive or pulmonary bleeding that leads to death in 35 to 70% of cases. Transmission of Ebola between humans occurs mainly via direct contact with the disease or with infected biological products, rather than by the air-borne route. Clinical manifestations appear after a 4-16 day incubation period, initially with fever, cephalalgia, myalgia and conjunctival suffusion. Digestive symptoms then appear, including nausea, vomiting, and diarrhea, and are associated with leuco- thrombocytopenia. The next stage is marked by hemorrhage in the nose, intestines or genitalia. Biological findings include an isolated elevation of transaminases and stigmatas of disseminated intravascular coagulation. The disease is usually fatal within a few days. Etiology The reservoir for Lassa fever is a rodent which transmits the virus to humans directly, with no need of a vector. Ebola and Marburg viruses belong to the filoviridae viral family, but their reservoirs remain unknown. The source of the first documented Marburg epidemic was a group of African green monkeys imported from Uganda. Ebola virus causes deadly localized epidemics centered around central Africa. Management and treatment Treatment is symptomatic. Secondary prevention within hospital services consists of the total isolation of affected patients. The disease is notifiable.

MalaCards based summary : Viral Hemorrhagic Fever, also known as hemorrhagic fevers, viral, is related to ebola hemorrhagic fever and lassa fever, and has symptoms including fever and pruritus. An important gene associated with Viral Hemorrhagic Fever is LBR (Lamin B Receptor). The drugs tannic acid and Benzocaine have been mentioned in the context of this disorder. Affiliated tissues include liver, endothelial and monocytes, and related phenotypes are fatigue and fever

Wikipedia : 73 Viral hemorrhagic fevers (VHFs) are a diverse group of animal and human illnesses in which fever and... more...

Related Diseases for Viral Hemorrhagic Fever

Diseases related to Viral Hemorrhagic Fever via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 52)
# Related Disease Score Top Affiliating Genes
1 ebola hemorrhagic fever 11.2
2 lassa fever 11.2
3 marburg hemorrhagic fever 11.2
4 dengue disease 11.1
5 omsk hemorrhagic fever 11.1
6 arbovirosis 11.1
7 crimean-congo hemorrhagic fever 10.5
8 yellow fever 10.4
9 rift valley fever 10.4
10 coccidioidomycosis 10.4
11 dengue virus 10.3
12 thrombocytopenia 10.3
13 bacterial sepsis 10.2
14 korean hemorrhagic fever 10.2
15 hantavirus hemorrhagic fever with renal syndrome 10.2
16 lymphocytic choriomeningitis 10.2
17 chikungunya 10.1
18 disease by infectious agent 10.1
19 exanthem 10.1
20 kyasanur forest disease 10.1
21 cholera 10.1
22 plague 10.1
23 encephalitis 10.1
24 west nile virus 10.0
25 malaria 10.0
26 tick-borne encephalitis 10.0
27 variola major 10.0
28 murray valley encephalitis 10.0
29 japanese encephalitis 10.0
30 st. louis encephalitis 10.0
31 respiratory failure 10.0
32 hemopericardium 10.0
33 pericardial effusion 10.0
34 allergic disease 10.0
35 neutropenia 10.0
36 dysentery 10.0
37 typhoid fever 10.0
38 hantavirus pulmonary syndrome 10.0
39 lymphadenitis 10.0
40 vascular disease 10.0
41 leptospirosis 10.0
42 west nile encephalitis 10.0
43 acute kidney failure 10.0
44 monkeypox 10.0
45 vaccinia 10.0
46 smallpox 10.0
47 cowpox 10.0
48 fatty liver disease 10.0
49 47,xyy 10.0
50 secondary hemophagocytic lymphohistiocytosis 10.0

Graphical network of the top 20 diseases related to Viral Hemorrhagic Fever:



Diseases related to Viral Hemorrhagic Fever

Symptoms & Phenotypes for Viral Hemorrhagic Fever

Human phenotypes related to Viral Hemorrhagic Fever:

31 (show all 24)
# Description HPO Frequency HPO Source Accession
1 fatigue 31 hallmark (90%) HP:0012378
2 fever 31 hallmark (90%) HP:0001945
3 nausea and vomiting 31 frequent (33%) HP:0002017
4 thrombocytopenia 31 frequent (33%) HP:0001873
5 abdominal pain 31 frequent (33%) HP:0002027
6 arthralgia 31 frequent (33%) HP:0002829
7 myalgia 31 frequent (33%) HP:0003326
8 gastrointestinal hemorrhage 31 frequent (33%) HP:0002239
9 epistaxis 31 frequent (33%) HP:0000421
10 migraine 31 frequent (33%) HP:0002076
11 chest pain 31 frequent (33%) HP:0100749
12 skin rash 31 frequent (33%) HP:0000988
13 gingival bleeding 31 frequent (33%) HP:0000225
14 subcutaneous hemorrhage 31 frequent (33%) HP:0001933
15 diarrhea 31 frequent (33%) HP:0002014
16 leukopenia 31 frequent (33%) HP:0001882
17 spontaneous abortion 31 frequent (33%) HP:0005268
18 decreased liver function 31 frequent (33%) HP:0001410
19 encephalitis 31 occasional (7.5%) HP:0002383
20 hearing impairment 31 occasional (7.5%) HP:0000365
21 reduced consciousness/confusion 31 occasional (7.5%) HP:0004372
22 retrobulbar optic neuritis 31 occasional (7.5%) HP:0100654
23 seizure 31 occasional (7.5%) HP:0001250
24 recurrent bronchiolitis 31 occasional (7.5%) HP:0100501

UMLS symptoms related to Viral Hemorrhagic Fever:


fever; pruritus

Drugs & Therapeutics for Viral Hemorrhagic Fever

Drugs for Viral Hemorrhagic Fever (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 22)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
tannic acid Approved Phase 3 1401-55-4
2
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
3 Heptavalent Pneumococcal Conjugate Vaccine Phase 3
4 Pharmaceutical Solutions Phase 3
5 polysaccharide-K Phase 3
6 Vaccines Phase 3
7 Immunologic Factors Phase 3
8
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754
9
Hydrocortisone acetate Approved, Vet_approved Phase 2 50-03-3
10
Ivermectin Approved, Investigational, Vet_approved Phase 2 70288-86-7 6474909
11
Epinephrine Approved, Vet_approved Phase 2 51-43-4 5816
12
Racepinephrine Approved Phase 2 329-65-7 838
13 Hydrocortisone hemisuccinate Phase 2
14 Hydrocortisone 17-butyrate 21-propionate Phase 2
15 Hemostatics Phase 2
16 Antiparasitic Agents Phase 2
17 Epinephryl borate Phase 2
18
Formaldehyde Approved, Vet_approved Phase 1 50-00-0 712
19 Immunoglobulins
20 Antibodies
21 Anti-Bacterial Agents
22 Antibiotics, Antitubercular

Interventional clinical trials:

(show top 50) (show all 68)
# Name Status NCT ID Phase Drugs
1 Immunogenicity and Safety of a Booster Injection of DTaP-IPV//Hib (Pentaxim™) Administered Concomitantly With Tetravalent Dengue Vaccine in Healthy Toddlers Aged 15 to 18 Months in Mexico Completed NCT01411241 Phase 3
2 Immunogenicity and Safety of Yellow Fever Vaccine (Stamaril®) Administered Concomitantly With Tetravalent Dengue Vaccine in Healthy Toddlers at 12-13 Months of Age in Colombia and Peru Completed NCT01436396 Phase 3
3 Safety and Immunogenicity of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia Completed NCT01254422 Phase 3
4 Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia Completed NCT01373281 Phase 3
5 Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America Completed NCT01374516 Phase 3
6 Lot-to-Lot Consistency and Bridging Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia Completed NCT01134263 Phase 3
7 [rVSVΔG-ZEBOV] Ebola Prevention Vaccine Evaluation in Sierra Leone Completed NCT02378753 Phase 2, Phase 3
8 Emergency Evaluation of Convalescent Plasma for Ebola Viral Disease (EVD) in Guinea Completed NCT02342171 Phase 2, Phase 3
9 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix® in Healthy Female Subjects Aged 9 to 14 Years in Mexico Completed NCT02979535 Phase 3
10 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil® in Healthy Subjects Aged 9 to 13 Years in Malaysia Completed NCT02993757 Phase 3
11 A Multi-country, Prospective, Clinical Safety Study of Subjects Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo Active, not recruiting NCT02661464 Phase 3
12 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects Aged 9 to 60 Years in the Philippines Terminated NCT02992418 Phase 3
13 Syndrome of Fever Associated With Bleeding of Chinese and Western Medicine Diagnosis and Treatment of Infectious Diseases Plans and Severe Clinical Treatment Research Unknown status NCT01973855 Phase 2 Western Medicine;TCM and Western Medicine
14 Immunogenicity and Safety of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects Aged 2 to 45 Years in Viet Nam Completed NCT00875524 Phase 2
15 A Randomized, Observer-blind, Placebo-controlled, Phase 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Different Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebola Ad26.ZEBOV and MVA-BN-Filo in Healthy Adults, Including Elderly Subjects, HIV-infected Subjects, and Healthy Children in Two Age Strata in Africa Completed NCT02564523 Phase 2
16 Immunogenicity and Safety of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India. Completed NCT01550289 Phase 2
17 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Given as a Booster Injection in Adolescents and Adults Who Previously Completed the 3-dose Schedule in a Study Conducted in Singapore Completed NCT02824198 Phase 2
18 Immunogenicity and Large-Scale Safety of Tetravalent Dengue Vaccine in Healthy Subjects Aged 2 to 45 Years in Singapore Completed NCT00880893 Phase 2
19 Efficacy and Safety of Dengue Vaccine in Healthy Children Aged 4 to 11 Years in Thailand Completed NCT00842530 Phase 2
20 A Multi-centre, Randomised, Double-blind, Parallel Group, Placebo-controlled Comparison of Recombinant Factor VIIa (NovoSeven®) and Standard Haemostatic Replacement Therapy in Patients With Dengue Haemorrhagic Fever Completed NCT01601613 Phase 2 activated recombinant human factor VII;placebo
21 Immunogenicity and Safety of Tetravalent Dengue Vaccine Given in 1-, 2-, or 3- Dose Schedules (STAGE I) Followed by a Single Booster Injection of the Same Vaccine (STAGE II) 1 or 2 Years After the Last Primary Dose in Healthy Subjects 9 to 50 Years of Age in Colombia and the Philippines Completed NCT02628444 Phase 2
22 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Given as a Booster Injection in Adolescents and Adults Who Previously Completed the 3-dose Schedule in a Study Conducted in Latin America Completed NCT02623725 Phase 2
23 Immunogenicity and Safety of CYD Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines Completed NCT01064141 Phase 2
24 Safety and Immunogenicity of Bivalent and Tetravalent Formulations of Dengue Vaccine Candidates in Healthy Flavivirus-Naïve Adults Aged 18 to 45 Years Completed NCT00740155 Phase 2
25 A Randomized, Observer-blind, Placebo-controlled, Two-part, Phase 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebola Ad26.ZEBOV and MVA-BN-Filo Completed NCT02598388 Phase 2
26 Immunogenicity and Safety of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years Previously Vaccinated Against Yellow Fever in Peru Completed NCT00788151 Phase 2
27 Safety of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects Previously Immunised With an Investigational Dengue or Yellow Fever Vaccine Completed NCT00730288 Phase 2
28 Immunogenicity and Safety of Three Tetravalent Formulations of Dengue Vaccine Candidates in Healthy Adults Aged 18 to 45 Years in the US Completed NCT00617344 Phase 2
29 Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America Completed NCT00993447 Phase 2
30 Immunogenicity and Safety of CYD Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in South America Completed NCT01187433 Phase 2
31 Pharmacokinetics and Pharmacodynamics of Ivermectin in Pediatric Dengue Patients Completed NCT03432442 Phase 2 Ivermectin
32 Phase II, Randomized, Double-blind, Placebo-controlled Study of Two Doses of WRAIR Live Attenuated Tetravalent Dengue Vaccine Formulations, Administered Six Months Apart, to Healthy Adults and Children Completed NCT00468858 Phase 2
33 Exploration of Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity Following Various Administration Schedules With CYD Tetravalent Dengue Vaccine Completed NCT01943825 Phase 2
34 A Phase 2a Double-Blind, Dose-optimizing Study to Evaluate the Immunogenicity of Hantaan/Puumala Virus DNA Vaccine Administered to Healthy Adult Volunteers by Electroporation for Prevention of Hemorrhagic Fever With Renal Syndrome Completed NCT02116205 Phase 2
35 Evaluation of the Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Administered With or Without Yellow Fever Vaccine in US Adults. Completed NCT01488890 Phase 2
36 Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults Aged 18 to 50 Years in Brazil Active, not recruiting NCT02741128 Phase 2
37 A Phase 2 Treatment Protocol of Intravenous Ribavirin in Adult Subjects With Hemorrhagic Fever With Renal Syndrome (HFRS) in the 121st Combat Support Hospital (Seoul, Korea) Enrolling by invitation NCT00623168 Phase 2 Ribavirin
38 Treatment Protocol for Adults With Hemorrhagic Fever With Renal Syndrome (HFRS) With Intravenous (IV) Ribavirin Not yet recruiting NCT04283513 Phase 2 Virazole
39 A Phase 2A, Randomized, Double-Blind Study To Evaluate The Safety And Immunogenicity Of A Hantaan Virus DNA Vaccine And A Puumala Virus DNA Vaccine, For The Prevention Of Hemorrhagic Fever With Renal Syndrome, Administered To Healthy Adult Volunteers Using The Pharmajet Stratis® Needle-Free Jet Injection Delivery Device Not yet recruiting NCT04333459 Phase 2
40 Treatment of Viral Hemorrhagic Fever (Crimean-Congo Hemorrhagic Fever or Lassa Fever) With Intravenous Ribavirin in Department of Defense (DOD) Associated Medical Treatment Facilities: A Phase 2 Study Withdrawn NCT00992693 Phase 2 Ribavirin (Virazole) Injection
41 A Phase 2 Treatment Protocol of Intravenous Ribavirin in Adult Subjects With Hemorrhagic Fever With Renal Syndrome (HFRS) in Landstuhl Regional Medical Center (Landstuhl, Germany) IND 16,666 Withdrawn NCT00868946 Phase 2 Virazole (Ribavirin)
42 A Double-blind, Placebo-controlled, Dose-escalation Study of the Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of LHF-535 (LHF-535-SDD) in Healthy Participants Completed NCT03993704 Phase 1 LHF-535
43 A Phase I Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-6002 in Healthy Adult Volunteers Completed NCT01353027 Phase 1 Placebo;AVI-6002
44 Phase I Evaluation of the Safety and Immunogenicity of rDEN4delta30 Lot# 109A, a Live Attenuated DEN4 Vaccine, in Healthy Flavivirus-naïve Adult Volunteers. Completed NCT00919178 Phase 1
45 A Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-6003 in Healthy Adult Volunteers Completed NCT01353040 Phase 1 AVI-6003;Placebo
46 A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7288 in Healthy Adult Volunteers Completed NCT01566877 Phase 1 AVI-7288
47 Phase 1 Evaluation of a Live Attenuated Human Parainfluenza Virus Type 3 Vectored Vaccine Candidate Expressing Ebolavirus Zaire Glycoprotein Completed NCT02564575 Phase 1
48 An Open Label, Single Center, Dose Escalation Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of a Single Ascending Dose of the Ebola Virus Vaccine rVSVΔG-ZEBOV-GP (BPSC1001) Completed NCT02283099 Phase 1
49 A Phase 1b, Dose-escalating Safety and Immunogenicity Trial of the Novel Monovalent Ebola Zaire Candidate Vaccine, cAd3-EBO Z and the Heterologous Prime-boost Candidate Vaccine Regimen of cAD3-EBO Z Followed by MVA-BN® Filo in Malian Adults Aged 18-50 Years. Completed NCT02267109 Phase 1
50 A PHASE IB, DOUBLE-BLIND, CLINICAL TRIAL TO EVALUATE THE SAFETY, TOLERABILITY AND IMMUNOGENICITY OF TWO DIFFERENT DOSAGE LEVELS OF EBOLA CHIMPANZEE ADENOVIRUS VECTOR VACCINE "VRC-EBOADC069-00-VP (cAd3-EBO)" AND THE HETEROLOGOUS PRIME-BOOST CANDIDATE VACCINE REGIMEN OF cAD3-EBO FOLLOWED BY MVA-VECTORED VACCINE IN HEALTHY ADULTS, 18-65 YEARS OF AGE, IN BAMAKO, MALI Completed NCT02368119 Phase 1

Search NIH Clinical Center for Viral Hemorrhagic Fever

Genetic Tests for Viral Hemorrhagic Fever

Anatomical Context for Viral Hemorrhagic Fever

MalaCards organs/tissues related to Viral Hemorrhagic Fever:

40
Liver, Endothelial, Monocytes, T Cells, Kidney, Myeloid

Publications for Viral Hemorrhagic Fever

Articles related to Viral Hemorrhagic Fever:

(show top 50) (show all 420)
# Title Authors PMID Year
1
The First Outbreak of Crimean-Congo Hemorrhagic Fever Disease in Northwest of Iran. 61
33674967 2021
2
Immunity against Lagovirus europaeus and the Impact of the Immunological Studies on Vaccination. 61
33805607 2021
3
Immunoinformatics analysis to design novel epitope based vaccine candidate targeting the glycoprotein and nucleoprotein of Lassa mammarenavirus (LASMV) using strains from Nigeria. 61
33719908 2021
4
Pathogen Dose in Animal Models of Hemorrhagic Fever Virus Infections and the Potential Impact on Studies of the Immune Response. 61
33804381 2021
5
Institutional policies and readiness in management of critical illness among patients with viral hemorrhagic fever. 61
33583468 2021
6
Mining of Ebola virus genome for the construction of multi-epitope vaccine to combat its infection. 61
33463407 2021
7
Lassa Virus Circulation in Small Mammal Populations in Bo District, Sierra Leone. 61
33466234 2021
8
Chainchecker: An application to visualise and explore transmission chains for Ebola virus disease. 61
33606709 2021
9
The NF-κB inhibitor, SC75741, is a novel antiviral against emerging tick-borne bandaviruses. 61
33296695 2021
10
Systemic viral spreading and defective host responses are associated with fatal Lassa fever in macaques. 61
33398113 2021
11
Preparedness of health care systems for Ebola outbreak response in Kasese and Rubirizi districts, Western Uganda. 61
33509138 2021
12
A novel circulating tamiami mammarenavirus shows potential for zoonotic spillover. 61
33370288 2020
13
A lateral flow biosensor based on gold nanoparticles detects four hemorrhagic fever viruses. 61
33184619 2020
14
Impact of C-Reactive Protein Levels on Differentiating of Severe Fever With Thrombocytopenia Syndrome From Japanese Spotted Fever. 61
33204759 2020
15
Yellow fever in children and adolescents previously immunized in Minas Gerais State, Brazil. 61
32950299 2020
16
Severe Human Lassa Fever Is Characterized by Nonspecific T-Cell Activation and Lymphocyte Homing to Inflamed Tissues. 61
32817220 2020
17
Protective and pathogenic roles for mast cells during viral infections. 61
32563779 2020
18
Impact of admission to high-risk isolation room on patients' and healthcare workers' perceptions: A qualitative cross-assessment Approach. 61
33164835 2020
19
A Rare Fatal Cause of Acute Areflexic Quadriparesis in the Tropics. 61
33109875 2020
20
A Model for the Production of Regulatory Grade Viral Hemorrhagic Fever Exposure Stocks: From Field Surveillance to Advanced Characterization of SFTSV. 61
32872451 2020
21
Adjuvant formulated virus-like particles expressing native-like forms of the Lassa virus envelope surface glycoprotein are immunogenic and induce antibodies with broadly neutralizing activity. 61
33574321 2020
22
Fragment screening targeting Ebola virus nucleoprotein C-terminal domain identifies lead candidates. 61
32446802 2020
23
Review of data and knowledge gaps regarding yellow fever vaccine-induced immunity and duration of protection. 61
33574318 2020
24
Patent landscape of novel technologies for combating category-A Arenavirus infections. 61
32274944 2020
25
Adaptive genetic diversification of Lassa virus associated with the epidemic split of north-central Nigerian and non-Nigerian lineages. 61
32174454 2020
26
Molecular Mechanism for Protection Against Liver Failure in Human Yellow Fever Infection. 61
32363317 2020
27
Type I interferon underlies severe disease associated with Junín virus infection in mice. 61
32452770 2020
28
Lassa Virus Genetics. 61
32418034 2020
29
Pre-positioned Outbreak Research: The Joint Medical Emerging Diseases Intervention Clinical Capability Experience in Uganda. 61
32324070 2020
30
Delayed-onset paraparesis in Lassa fever: A case report. 61
31866549 2020
31
The Utility of Human Immune System Mice for High-Containment Viral Hemorrhagic Fever Research. 61
32098330 2020
32
Quality of age data in the Sierra Leone Ebola database. 61
32637002 2020
33
Adjuvant formulated virus-like particles expressing native-like forms of the Lassa virus envelope surface glycoprotein are immunogenic and induce antibodies with broadly neutralizing activity. 61
32802410 2020
34
Review of data and knowledge gaps regarding yellow fever vaccine-induced immunity and duration of protection. 61
32655896 2020
35
The Ebola Virus Nucleoprotein Recruits the Nuclear RNA Export Factor NXF1 into Inclusion Bodies to Facilitate Viral Protein Expression. 61
31940815 2020
36
Guinea Pig Transferrin Receptor 1 Mediates Cellular Entry of Junín Virus and Other Pathogenic New World Arenaviruses. 61
31748396 2020
37
Emerging and re-emerging infectious diseases in Japan: epidemiology and infection prevention measures. 61
33330759 2019
38
Lassa fever in pregnancy with a positive maternal and fetal outcome: A case report. 61
31465848 2019
39
Rousette Bat Dendritic Cells Overcome Marburg Virus-Mediated Antiviral Responses by Upregulation of Interferon-Related Genes While Downregulating Proinflammatory Disease Mediators. 61
31801842 2019
40
Phylogeography of Lassa Virus in Nigeria. 61
31413134 2019
41
Emerging Infectious Diseases and Antimicrobial Resistance (EIDAR). 61
31004432 2019
42
Hantavirus infection in Iranian patients suspected to viral hemorrhagic fever. 61
31218696 2019
43
Yellow Fever: Integrating Current Knowledge with Technological Innovations to Identify Strategies for Controlling a Re-Emerging Virus. 61
31627415 2019
44
Immune Modulation and Immune-Mediated Pathogenesis of Emerging Tickborne Banyangviruses. 61
31547199 2019
45
Vascular Leak and Hypercytokinemia Associated with Severe Fever with Thrombocytopenia Syndrome Virus Infection in Mice. 61
31546590 2019
46
Severe Fever with Thrombocytopenia Syndrome Phlebovirus causes lethal viral hemorrhagic fever in cats. 61
31427690 2019
47
Lassa fever diagnostics: past, present, and future. 61
31518896 2019
48
A short history of Lassa fever: the first 10-15 years after discovery. 61
31323506 2019
49
Application of therapeutic plasma exchange in patients having severe fever with thrombocytopenia syndrome. 61
29117665 2019
50
Development of an RT-LAMP assay for the detection of Lassa viruses in southeast and south-central Nigeria. 61
30974179 2019

Variations for Viral Hemorrhagic Fever

Expression for Viral Hemorrhagic Fever

Search GEO for disease gene expression data for Viral Hemorrhagic Fever.

Pathways for Viral Hemorrhagic Fever

GO Terms for Viral Hemorrhagic Fever

Sources for Viral Hemorrhagic Fever

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....